Copper deficiency drives OXPHOS impairment and mitochondrial hyperfusion via MTCH2 in skeletal muscle

This study demonstrates that skeletal muscle-specific copper deficiency impairs mitochondrial respiration and induces pathological hyperfusion via the copper-binding protein MTCH2, leading to exercise intolerance and metabolic dysfunction that can be rescued by restoring copper levels.

The Gist

Imagine your body's muscles as a high-performance race car. For this car to run fast and long, it needs two things: a powerful engine (mitochondria) and the right fuel (copper).

This research paper tells the story of what happens when that race car runs out of a very specific, tiny, but essential ingredient: Copper.

Here is the breakdown of the story in simple terms:

1. The Missing Ingredient: Copper

Copper is like a tiny spark plug in your muscles' engines. Without it, the engine (specifically a part called "Complex IV") can't fire properly. Scientists knew copper was important, but they didn't fully understand how the muscles in our legs and arms managed to get enough of it to keep us running.

2. The Experiment: Cutting Off the Supply

The researchers created a special group of mice where they "turned off" the main door (a protein called CTR1) that lets copper enter the muscle cells.

• The Result: These mice were like race cars with a clogged fuel line. They couldn't run far, their grip strength was weak, and their muscles were tired.
• The Mystery: Even though the mice tried to switch to a "slow-twitch" engine type (which is usually better for endurance), it didn't help. Their engines were still broken because they lacked the copper spark plugs.

3. The Discovery: The "Gatekeeper" Protein (MTCH2)

The scientists found a hero protein hiding in the outer wall of the mitochondria called MTCH2. Think of MTCH2 as a bouncer at a club or a gatekeeper.

• How it works: MTCH2 has a special job. It grabs copper and helps move it inside the engine room so the spark plugs can work.
• The Twist: This gatekeeper is also very sensitive to copper levels.
  • When copper is low: The gatekeeper (MTCH2) gets scared and sticks around, refusing to leave. In doing so, it accidentally forces all the mitochondria to fuse together into one giant, tangled web (like a ball of yarn). This is called "hyperfusion." It's the cell's desperate, messy attempt to survive, but it actually makes the engine run worse.
  • When copper is high: The gatekeeper realizes the job is done and gets recycled (destroyed) so the mitochondria can stay separate and efficient.

4. The Fix: Two Ways to Restart the Engine

The researchers wanted to see if they could fix these broken mice. They tried two different "rescue missions":

• Mission A: The Copper Courier (Elesclomol)
  They used a special drug (an ionophore) that acts like a courier service. Instead of using the broken front door (CTR1), this courier sneaks copper directly into the cell.

  • Outcome: It worked! The muscles got their spark plugs back, the tangled mitochondria untangled, and the mice could run again.

• Mission B: The New Door (AAV Gene Therapy)
  They used a virus (AAV) to deliver a brand-new copy of the "front door" (CTR1) gene directly into the muscles.

  • Outcome: This also worked perfectly. The muscles could finally let copper in on their own, the engines fired up, and the mice returned to normal health.

The Big Picture

This study teaches us three main things:

1. Copper is non-negotiable: Your muscles absolutely need copper to function, not just for building, but for daily energy.
2. The Gatekeeper is key: The protein MTCH2 is a double agent. It helps move copper, but it also acts as a sensor. When copper is missing, it changes the shape of the mitochondria, which is a sign that the cell is in trouble.
3. Hope for the future: Since we can fix this in mice by either smuggling in copper or fixing the door, this opens up new ways to treat human diseases where muscles fail due to copper issues (like Menkes disease or certain types of mitochondrial myopathy).

In short: The paper shows that without copper, your muscles' engines sputter and their internal wiring gets tangled. But if you can get that copper back in—either by a clever drug or gene therapy—you can untangle the mess and get the race car running at full speed again.

Technical Summary

1. Problem Statement

Copper is an essential trace element required for mitochondrial respiration, specifically as a cofactor for Cytochrome c Oxidase (Complex IV) in the Electron Transport Chain (ETC). While the systemic regulation of copper is well-characterized, the physiological role of copper in mature skeletal muscle and the molecular mechanisms linking copper homeostasis to mitochondrial dynamics remain poorly understood. Previous studies suggested copper deficiency alters mitochondrial morphology (e.g., upregulation of fusion proteins), but the specific sensors and effectors driving this remodeling were unknown. This study aims to define the consequences of skeletal muscle-specific copper deficiency and identify the molecular machinery connecting copper levels to mitochondrial structure and function.

2. Methodology

The researchers employed a multi-faceted approach combining in vivo mouse models, in vitro cell culture, proteomics, structural biology, and therapeutic interventions:

• Animal Models: Generated Skeletal Muscle-specific Knockout (SMKO) mice by crossing Ctr1-floxed mice with Myl1-Cre transgenic mice to delete the high-affinity copper importer CTR1 specifically in skeletal muscle.
• Phenotypic Analysis: Conducted exercise tolerance tests (treadmill, grip strength), indirect calorimetry (VO2, VCO2, energy expenditure), and histological assessments (SDH, Gomori trichrome, TEM) to evaluate muscle health and mitochondrial morphology.
• Proteomics: Performed mass spectrometry on gastrocnemius (GA) muscle tissue to identify differentially expressed proteins (DEPs) and Electron Transport Chain (ETC) imbalances.
• Molecular Mechanism & Structural Biology:
  • Identified MTCH2 (Mitochondrial Carrier Homolog 2) as a candidate copper-binding protein.
  • Used AlphaFold 3 and SWISS-MODEL to predict MTCH2 structure and identify copper-binding residues (specifically a sulfur-rich cluster: M244, C268, M278).
  • Validated copper binding using in vitro resin assays and mutagenesis (alanine substitution).
  • Investigated protein turnover via ubiquitination assays and proteasome inhibition (MG132).
• Therapeutic Rescue:
  • Elesclomol (ES): Administered a copper ionophore to bypass CTR1 and deliver copper intracellularly.
  • AAV-DIO-Ctr1: Used an adeno-associated virus (AAV9) with a Cre-dependent system to re-express Ctr1 specifically in SMKO muscle.

3. Key Contributions

• Discovery of a Dual-Function Protein: The study identifies MTCH2 as a critical, dual-function regulator that acts as both a copper trafficker across the outer mitochondrial membrane (OMM) and a copper-sensitive switch for mitochondrial fusion.
• Mechanism of Copper-Dependent Turnover: The authors elucidate that copper binding to specific sulfur-rich residues on MTCH2 triggers its polyubiquitination and proteasomal degradation. Conversely, copper starvation stabilizes MTCH2.
• Resolution of a Paradox: The paper reconciles conflicting literature regarding MTCH2. While MTCH2 deletion in healthy muscle improves metabolism, this study shows that under severe copper starvation, the stabilization of MTCH2 drives pathological hyperfusion.
• Therapeutic Validation: Demonstrates that both pharmacological copper delivery (ionophore) and gene therapy (AAV-mediated Ctr1 restoration) can fully reverse mitochondrial myopathy in copper-deficient muscle.

4. Key Results

A. Physiological Consequences of Copper Deficiency (SMKO Mice)

• Exercise Intolerance: SMKO mice exhibited severe deficits in grip strength and endurance running.
• Metabolic Reprogramming: Despite a shift toward oxidative (slow-twitch) fiber types (Type I/IIa), SMKO mice showed reduced oxygen consumption (VO2) and suppressed energy expenditure.
• Bioenergetic Collapse: There was a profound reduction in mitochondrial respiration (OCR) and ATP levels, forcing a compensatory shift to glycolysis, evidenced by elevated circulating lactate (lactic acidosis).
• Mitochondrial Myopathy (MM) Phenotype: SMKO muscles displayed "ragged-red fibers," SDH hyperactivation, and enlarged, aberrant mitochondria, mimicking human mitochondrial myopathies.

B. Molecular Mechanisms: ETC Imbalance and MTCH2

• Proteomic Imbalance: SMKO muscle showed severe downregulation of Complex IV (COX) subunits (specifically MTCO1/COX1 and MTCO2/COX2), which are copper-dependent. This was accompanied by compensatory upregulation of Complexes I and II.
• MTCH2 as a Copper Sensor:
  • Binding: MTCH2 directly binds copper via a sulfur-rich motif (M244, C268, M278).
  • Stability: In copper-replete conditions, copper binding promotes MTCH2 ubiquitination and proteasomal degradation. In copper-deficient conditions (SMKO), MTCH2 is stabilized and accumulates.
  • Trafficking: MTCH2 is required for mitochondrial copper uptake; its knockdown reduces mitochondrial copper pools and impairs Complex IV assembly.

C. MTCH2 Drives Pathological Hyperfusion

• Hyperfusion: Copper starvation leads to MTCH2 accumulation, which drives excessive mitochondrial fusion (hyperfusion) via upregulation of MFN2 and OPA1.
• Causality: Silencing Mtch2 in copper-deficient cells completely abolished the elongation/hyperfusion phenotype, proving MTCH2 is the driver.
• Dual Role:
  1. Trafficking: MTCH2 facilitates copper entry into mitochondria to support COX activity.
  2. Dynamics: Accumulated MTCH2 (due to lack of copper-induced degradation) forces mitochondrial hyperfusion.

D. Therapeutic Rescue

• Elesclomol (ES): Treatment restored intracellular copper, reversed Complex IV depletion, normalized mitochondrial morphology (resolving ragged-red fibers), and restored exercise capacity in SMKO mice.
• AAV-Ctr1: Re-expression of Ctr1 in SMKO muscle similarly restored copper levels, corrected the ETC imbalance, normalized MTCH2 levels, and rescued metabolic and functional deficits.

5. Significance

• Mechanistic Insight: This study establishes a direct mechanistic link between cellular copper dyshomeostasis and mitochondrial architectural remodeling, mediated by the dual-function protein MTCH2.
• Clinical Relevance: The findings provide a molecular basis for muscle weakness in copper-deficiency disorders (e.g., Menkes disease) and suggest that mitochondrial hyperfusion is a pathological response to copper starvation, not just a compensatory mechanism.
• Therapeutic Potential: The successful reversal of mitochondrial myopathy via copper ionophores (Elesclomol) and gene therapy (AAV-Ctr1) highlights the copper-mitochondria axis as a promising, underexplored therapeutic target for treating metabolic myopathies, sarcopenia, and neurodegenerative diseases associated with copper dysregulation (e.g., ALS).
• Paradigm Shift: It challenges the view that mitochondrial fusion is always adaptive, showing that under specific nutrient stress (copper starvation), it becomes a pathological driver of dysfunction.